

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

# **Summary of investigation results**

# Inchinkoto for ethical use

July 8, 2014

# **Non-proprietary Name**

Inchinkoto

## **Brand Name (Marketing Authorization Holder)**

TSUMURA Inchinkoto extract granules for ethical use (Tsumura & Co.) and the others

#### **Indications**

Inchinkoto is indicated for the relief of the following symptoms of those patients with a comparatively strong constitution having somewhat tendency to constipation, and decreased urine volume:

Jaundice, hepatic cirrhosis, nephrosis, urticaria, and stomatitis

# **Summary of revision**

'Mesenteric phlebosclerosis' should be added in Clinically significant adverse reactions section.

## Background of the revision and investigation results

Cases of mesenteric phlebosclerosis have been reported in patients treated with Inchinkoto in Japan. Following an investigation result based of opinions of expert advisors and available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary.

## The number of reported adverse reaction and fatal cases in the last 3 fiscal years in Japan

A total of 5 mesenteric phlebosclerosis-associated cases has been reported (including 4 cases in which causality could not be ruled out). Of the 5 cases, no fatalities have been reported.